BioMedNewsBreaks

WednesdayFeb 01, 2023 1:44 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Bringing Quality-of-Life Improvements to Patients and Consumers

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health devices and wearable technology products for remote patient monitoring. The company “has, since inception, sought to offer quality-of-life improvements to patients and consumers who have Alzheimer’s, dementia and autism (‘ADA’)… Its flagship GPS SmartSoles HUB launched in the fourth quarter of the 2022 financial year, allowing for remote monitoring, data collection and encrypted data transmission to the cloud. In addition, RoomMate, MetAlert’s latest offering, allows caregivers to monitor patient behavior that could lead to falls and injuries without invading their privacy. As evidenced by these two products, MetAlert prioritizes patient confidentiality…

Continue Reading

WednesdayFeb 01, 2023 11:30 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Reappointment of Dr. Hector Alila to Establish Advisory Group

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced that Dr. Hector Alila has rejoined its board of directors with the specific responsibility of building a technical advisory board. “We are pleased to welcome Hector back to our board. With our focus on new scientific and clinical programs, our immediate need is to build a top-tier team of technical advisors to review our R&D activities and scientific approaches,” said Dr. Glynn Wilson, board chairman. “Dr. Alila brings 30 years of experience in translating novel research into clinical programs and product opportunities. He was most…

Continue Reading

WednesdayFeb 01, 2023 11:16 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being conducted at the Centre for Human Drug Research in the Netherlands; it is the largest-ever Phase 1 DMT trial conducted to date. Based on previous studies, CYB004 has shown potential to deliver an improved bioavailability…

Continue Reading

TuesdayJan 31, 2023 11:20 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has announced a stock repurchase program. According to the company, its board of directors has approved the program, which will acquire up to $1 million of the company's common stock. The announcement noted that the company could purchase common stock in a variety of ways, including in the open market and through privately negotiated transactions; all transactions will be in compliance with United States Securities and Exchange Commission rules and guidelines. The repurchase of stocks will depend on available liquidity, cash flows and market conditions…

Continue Reading

MondayJan 30, 2023 11:00 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS (“MCAD”) at two clinical sites in the USA, with a Canadian site to be ready to recruit soon. “FSD201 is a unique proprietary formulation of palmitoyl ethanolamide, and already received the new molecular entity (‘NME’) designation for a potential 505(b)(1) application to the U.S. FDA. This…

Continue Reading

ThursdayJan 26, 2023 1:45 pm

BioMedNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Featured in New Article

MetAlert (OTC: MLRT), a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders, recently announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec LLC. Offering affordable, scalable location-awareness technology solutions, TrakTec made the news in a new Fairmont Post article that discusses its SafetyNet(R) service and others like it that are providing peace of mind for caregivers and loved ones and helping to quickly locate individuals who may be in danger. “Many police departments in the country have already begun to take advantage of these technologies to locate and rescue…

Continue Reading

ThursdayJan 26, 2023 11:54 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for the treatment of major depressive disorder, and CYB004, which is being evaluated for the treatment of generalized anxiety disorder. According to the announcement, the event will feature an interim readout from CYBN’s ongoing phase 1/2a…

Continue Reading

WednesdayJan 25, 2023 12:54 pm

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms

India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently there is no FDA-approved medication to treat agitation in Alzheimer’s,” reads a recent article. The piece quotes IGC CEO Ram Mukunda, who states, “We believe IGC-AD1 has the potential to revolutionize the treatment of the…

Continue Reading

WednesdayJan 25, 2023 11:38 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Its Next-Gen SmartSole in Sweden

MetAlert (OTC: MLRT) today announced the launch of its new 4G GPS SmartSole in Sweden through its distribution partner Posifon AB. The upgraded GPS SmartSole introduction will be an important part of the national service agreement Posifon recently secured with major municipalities across Sweden related to providing home care, personal tracking and security for seniors. Initial shipments of the GPS SmartSole will be distributed to health care organizations, from memory care clinics to hospitals and social care organizations throughout Sweden. “We are excited to launch this next generation 4G Cat M1 GPS SmartSole in one of Europe’s most advanced health…

Continue Reading

WednesdayJan 25, 2023 10:26 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) $4.1M Placements Supported by Aegis Capital Corp. as Exclusive Placement Agent

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, recently announced the closing of both a registered direct and a private placement; the placements totaled approximately $4.1 million. Aegis Capital Corp. acted as exclusive placement agent for those placements. In the wealth management and investment banking business since 1984, Aegis has built a reputation for offering corporate finance and strategic advisory services to public and private companies across multiple sectors and regions. In addition, the company offers expert research and sales and trading services to institutional investors. Aegis provides a conflict-free service platform as well as…

Continue Reading